Fig. 2: The dominant mutations at relapse are already present at the start of therapy. | Blood Cancer Journal

Fig. 2: The dominant mutations at relapse are already present at the start of therapy.

From: Circulating tumour DNA analysis predicts relapse and improves risk stratification in primary refractory multiple myeloma

Fig. 2

A Schematic of the analysis performed to assess the kinetics of ctDNA during treatment and subsequent relapse. B–Q Sequential ctDNA TAS analysis of 16 patients that relapsed with the VAF of the mutations present at each of the time points shown in the line graph. In 87.5% of the patients, at least one mutation at relapse/pre-relapse was already present at the start of therapy. cfDNA cell-free DNA, ctDNA circulating tumour DNA, BM bone marrow, C3D1 cycle 3 day 1, EOS end of study, VAF variant allele frequency, TAS targeted amplicon sequencing. Figures were generated using Biorender.com.

Back to article page